| Literature DB >> 32908502 |
Xiaoming Lou1, Xiaofeng Wang1, Zhifang Wang1, Guangming Mao1, Wenming Zhu1, Yuanyang Wang1, Xuejiao Pan1, Zhijian Chen1, Zhe Mo1.
Abstract
OBJECTIVE: The aim of this study was to explore whether iodine nutrition is associated with the risk of thyroid nodules among adult population in Zhejiang Province, China.Entities:
Year: 2020 PMID: 32908502 PMCID: PMC7450337 DOI: 10.1155/2020/3760375
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Summary statistics of variables between nonthyroid nodule and thyroid nodule groups.
| Variables | Nonthyroid nodule ( | Thyroid nodule ( | Total ( |
|
|---|---|---|---|---|
| Gendera | 0.00 | |||
| Female | 1108 (81.7) | 249 (18.4) | 1357 (50.1) | |
| Male | 1182 (87.4) | 171 (12.6) | 1353 (49.9) | |
| Age (yearb) | 42.40 (15.8) | 50.09 (15.5) | 43.0 (25.0) | 0.00 |
| Age groupa | 0.00 | |||
| 18–29 | 608 (91.8) | 54 (8.2) | 662 (24.4) | |
| 30–39 | 478 (88.4) | 63 (11.7) | 541 (20.0) | |
| 40–49 | 487 (85.0) | 86 (15.0) | 573 (21.1) | |
| 50–59 | 340 (79.1) | 90 (20.9) | 430 (15.9) | |
| 60–69 | 223 (75.1) | 74 (24.9) | 297 (11.0) | |
| ≥70 | 154 (74.4) | 53 (25.6) | 207 (7.6) | |
| Educationa | ||||
| Illiteracy/primary school | 521 (79.4) | 135 (20.6) | 656 (24.2) | |
| Junior middle school | 687 (83.5) | 136 (16.5) | 823 (30.4) | |
| High school/technical secondary school | 476 (87.8) | 66 (12.2) | 542 (20.0) | |
| University/college/graduate student | 606 (88.0) | 83 (12.0) | 689 (25.4) | |
| Professiona | 0.00 | |||
| Physical labor | 932 (84.4) | 172 (15.6) | 1104 (40.7) | |
| Agricultural labor | 275 (76.0) | 87 (24.0) | 362 (13.4) | |
| Mental labor | 694 (88.5) | 90 (11.5) | 784 (28.9) | |
| Others | 389 (84.6) | 71 (15.4) | 460 (17.0) | |
| Income, thousand yuana | 0.06 | |||
| <10 | 252 (88.1) | 34 (11.9) | 286 (10.6) | |
| 10–29 | 367 (82.8) | 76 (17.2) | 443 (16.4) | |
| 30–49 | 626 (82.0) | 137 (18.0) | 763 (28.2) | |
| 50–99 | 636 (85.6) | 107 (14.4) | 743 (27.4) | |
| ≥100 | 409 (86.1) | 66 (13.9) | 475 (17.5) | |
| Regiona | 0.41 | |||
| County | 1119 (85.1) | 196 (14.9) | 1315 (48.5) | |
| District | 1171 (83.9) | 224 (16.1) | 1395 (51.5) | |
| Smokea | 0.94 | |||
| No | 1874 (84.5) | 343 (15.5) | 2217 (81.8) | |
| Yes | 416 (84.4) | 77 (15.6) | 493 (18.2) | |
| Passive smokea | 0.82 | |||
| No | 1648 (84.6) | 300 (15.4) | 1948 (71.9) | |
| Yes | 642 (84.3) | 120 (15.7) | 762 (28.1) | |
| Family history of thyroid diseasesa | 0.60 | |||
| No | 2194 (84.6) | 400 (15.4) | 2594 (95.7) | |
| Yes | 96 (82.8) | 20 (17.2) | 116 (4.3) | |
| Hypertensiona | 0.00 | |||
| No | 1724 (86.1) | 278 (13.9) | 2002 (73.9) | |
| Yes | 566 (79.9) | 142 (20.1) | 708 (26.1) | |
| BMI (kg/m2b) | 23.4 (3.4) | 24.2 (3.2) | 23.6 ± 3.4 | 0.00 |
| Waist circumference (cmb) | 80.8 (9.5) | 84.7 (8.8) | 81.4 ± 9.5 | 0.00 |
| Heart rate (times/minuteb) | 79.7 (11.7) | 80.2 (11.2) | 79.8 ± 11.6 | 0.41 |
| FBG (mmol l−1b) | 5.5 (1.5) | 5.7 (1.3) | 5.5 ± 1.5 | 0.00 |
| OGTT-2h (mmol l−1b) | 5.9 (2.2) | 6.3 (2.4) | 5.9 ± 2.2 | 0.00 |
| HbA1cb | 5.4 (1.1) | 5.6 (0.8) | 5.5 ± 1.0 | 0.00 |
| TG (mmol l−1b) | 1.6 (2.9) | 1.6 (1.4) | 1.6 ± 2.7 | 0.96 |
| TC (mmol l−1b) | 4.6 (1.3) | 5.0 (1.1) | 4.7 ± 1.3 | 0.00 |
| LDL-C (mmol l−1b) | 2.8 (0.8) | 3.1 (0.9) | 2.9 ± 0.8 | 0.00 |
| HDL-C (mmol l−1b | 1.6 (0.5) | 1.6 (0.4) | 1.6 ± 0.5 | 0.32 |
| UA (mmol l−1b) | 297.1 (169.8) | 285.1 (84.7) | 295.2 ± 159.7 | 0.03 |
| TSH (mIU l−1c) | 2.2 (1.8) | 2.0 (1.4) | 2.2 (1.73) | 0.00 |
| Overt hyperthyroidisma | 1.00 | |||
| No | 2282 (84.5) | 419 (15.5) | 2701 (99.7) | |
| Yes | 8 (88.9) | 1 (11.1) | 9 (0.3) | |
| Subclinical hyperthyroidisma | 0.05 | |||
| No | 2287 (84.6) | 417 (15.4) | 2704 (99.8) | |
| Yes | 3 (50) | 3 (50) | 6 (0.2) | |
| Overt hypothyroidisma | 1.00 | |||
| No | 2275 (84.5) | 418 (15.5) | 2693 (99.4) | |
| Yes | 15 (88.2) | 2 (11.8) | 17 (0.6) | |
| Subclinical hyperthyroidisma | 0.05 | |||
| No | 1989 (84.5) | 366 (15.5) | 2355 (86.9) | |
| Yes | 314 (88.5) | 41 (11.5) | 355 (13.1) | |
| TPOAb (IU l−1c) | 11.5 (5.7) | 11.8 (5.7) | 11.6 (5.7) | 0.94 |
| TGAb (IU l−1c) | 12.5 (6.7) | 13.2 (7.3) | 12.6 (7.0) | 0.00 |
| Iodized salta | 0.00 | |||
| No | 706 (71.8) | 277 (28.2) | 983 (36.3) | |
| Yes | 1584 (91.7) | 143 (8.3) | 1727 (63.7) | |
| UIC ( | 164.0 (134.6) | 122.9 (110.3) | 158 (134.2) | 0.00 |
| UIC ( | 0.00 | |||
| <100 | 541 (23.6) | 158 (37.6) | 699 (25.8) | |
| 100–199 | 917 (40) | 165 (39.3) | 1082 (39.9) | |
| 200–299 | 530 (23.1) | 63 (15) | 593 (21.9) | |
| ≥300 | 302 (13.2) | 34 (8.1) | 336 (12.4) | |
aExpression with the number (proportion %), tested with the chi-square test. bExpression with mean (SD), tested with the t-test. cExpression with median (IQR), tested with the Wilcoxon method.
Figure 1The nonlinear and linear associations between urinary iodine concentration and prevalence of thyroid nodule: (a) the linear relationship between urinary iodine concentration and prevalence of thyroid nodule was observed with adjusted R2 = 73.6%; (b) the quadratic curve existed between urinary iodine concentration and prevalence of thyroid nodule with adjusted R2 = 98.6%; (c) the nonlinear relationship between urinary iodine concentration and prevalence of thyroid nodule was observed by using spline function with adjusted R2 = 98.5%.
Effect of urinary iodine concentration on thyroid nodule according to the iodine nutritional status evaluation criteria of the WHO.
| Group | UIC ( | Model 1a | Model 2b | Model 3c | Model 4d | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||
| All | <100 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 100–199 | 0.75 (0.58–0.97) | 0.03 | 0.75 (0.58–0.97) | 0.03 | 0.78 (0.61–1.01) | 0.06 | 0.79 (0.61–1.03) | 0.08 | |
| 200–299 | 0.54 (0.39–0.75) | 0.00 | 0.54 (0.39–0.75) | 0.00 | 0.62 (0.44–0.87) | 0.01 | 0.63 (0.45–0.88) | 0.01 | |
| ≥300 | 0.50 (0.34–0.76) | 0.00 | 0.51 (0.34–0.77) | 0.00 | 0.61 (0.40–0.92) | 0.02 | 0.62 (0.41–0.94) | 0.03 | |
|
| |||||||||
| Male | <100 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 100–199 | 0.83 (0.56–1.23) | 0.34 | 0.82 (0.55–1.22) | 0.33 | 0.84 (0.56–1.25) | 0.38 | 0.84 (0.56–1.25) | 0.39 | |
| 200–299 | 0.55 (0.34–0.91) | 0.02 | 0.55 (0.34–0.91) | 0.02 | 0.63 (0.38–1.04) | 0.07 | 0.63 (0.38–1.04) | 0.07 | |
| >300 | 0.67 (0.37–1.20) | 0.18 | 0.68 (0.38–1.21) | 0.19 | 0.84 (0.47–1.52) | 0.57 | 0.85 (0.47–1.53) | 0.58 | |
|
| |||||||||
| Female | <100 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 100–199 | 0.71 (0.51–0.98) | 0.04 | 0.71 (0.51–0.98) | 0.04 | 0.75 (0.54–1.05) | 0.09 | 0.77 (0.55–1.07) | 0.12 | |
| 200–299 | 0.54 (0.35–0.83) | 0.01 | 0.54 (0.35–0.84) | 0.01 | 0.62 (0.40–0.97) | 0.04 | 0.63 (0.40–0.98) | 0.04 | |
| ≥300 | 0.39 (0.22–0.70) | 0.00 | 0.40 (0.22–0.70) | 0.00 | 0.46 (0.25–0.82) | 0.01 | 0.47 (0.26–0.85) | 0.01 | |
aAdjusted for gender, age (continuous variable), education, and profession.bAdditionally adjusted for hypertension.cAdditionally adjusted for BMI, waist circumference, FBG, OTGG-2h, HbA1c, TC, LDL-C, and UA.dAdditionally adjusted for TSH and TGAb.
Effect of urinary iodine concentration on thyroid nodule according to the iodine nutritional status evaluation criteria of the WHO.
| Group | UIC ( | Model 1a | Model 2b | Model 3c | Model 4d | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||
| All | <100 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 100–199 | 0.75 (0.58–0.97) | 0.03 | 0.75 (0.58–0.97) | 0.03 | 0.78 (0.61–1.01) | 0.06 | 0.79 (0.61–1.03) | 0.08 | |
| 200–299 | 0.54 (0.39–0.75) | 0.00 | 0.54 (0.39–0.75) | 0.00 | 0.62 (0.44–0.87) | 0.01 | 0.62 (0.45–0.87) | 0.01 | |
| 300–399 | 0.43 (0.24–0.76) | 0.00 | 0.43 (0.24–0.76) | 0.00 | 0.52 (0.29–0.92) | 0.03 | 0.53 (0.30–0.94) | 0.03 | |
| 400–499 | 0.42 (0.18–1.00) | 0.05 | 0.42 (0.18–1.00) | 0.05 | 0.52 (0.21–1.25) | 0.14 | 0.52 (0.22–1.26) | 0.15 | |
| ≥500 | 0.73 (0.39–1.36) | 0.32 | 0.73 (0.39–1.37) | 0.33 | 0.85 (0.45–1.60) | 0.61 | 0.88 (0.47–1.67) | 0.71 | |
|
| |||||||||
| Male | <100 | ||||||||
| 100–199 | 0.83 (0.56–1.23) | 0.34 | 0.82 (0.55–1.22) | 0.33 | 0.84 (0.56–1.25) | 0.39 | 0.84 (0.56–1.25) | 0.39 | |
| 200–299 | 0.55 (0.34–0.91) | 0.02 | 0.55 (0.34–0.91) | 0.02 | 0.63 (0.38–1.04) | 0.07 | 0.63 (0.38–1.05) | 0.07 | |
| 300–399 | 0.57 (0.26–1.26) | 0.16 | 0.57 (0.26–1.26) | 0.17 | 0.74 (0.33–1.65) | 0.46 | 0.74 (0.33–1.66) | 0.47 | |
| 400–499 | 0.31 (0.07–1.34) | 0.12 | 0.31 (0.07–1.36) | 0.12 | 0.39 (0.09–1.74) | 0.22 | 0.39 (0.09–1.73) | 0.22 | |
| ≥500 | 1.29 (0.55–3.01) | 0.56 | 1.31 (0.56–3.05) | 0.53 | 1.48 (0.63–3.48) | 0.37 | 1.50 (0.64–3.54) | 0.35 | |
|
| |||||||||
| Female | <100 | ||||||||
| 100–199 | 0.71 (0.51–0.98) | 0.04 | 0.71 (0.51–0.98) | 0.04 | 0.75 (0.54–1.05) | 0.09 | 0.77 (0.55–1.07) | 0.12 | |
| 200–299 | 0.54 (0.35–0.83) | 0.01 | 0.54 (0.35–0.84) | 0.01 | 0.62 (0.40–0.97) | 0.04 | 0.63 (0.40–0.98) | 0.04 | |
| 300–399 | 0.33 (0.15–0.76) | 0.01 | 0.34 (0.15–0.76) | 0.01 | 0.38 (0.16–0.86) | 0.02 | 0.39 (0.17–0.89) | 0.03 | |
| 400–499 | 0.52 (0.18–1.54) | 0.24 | 0.52 (0.17–1.54) | 0.24 | 0.63 (0.21–1.88) | 0.40 | 0.63 (0.21–1.90) | 0.41 | |
| ≥500 | 0.42 (0.16–1.10) | 0.08 | 0.42 (0.16–1.11) | 0.08 | 0.50 (0.19–1.32) | 0.16 | 0.53 (0.20–1.39) | 0.20 | |
aAdjusted for gender, age (continuous variable), education, and profession.bAdditionally adjusted for hypertension.cAdditionally adjusted for BMI, waist circumference, FBG, OTGG-2h, HbA1c, TC, LDL-C, and UA.dAdditionally adjusted for TSH and TGAb.
Effect of iodized salt intake on thyroid nodule.
| Group | Iodized salt | Model 1a | Model 2b | Model 3c | Model 4d | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||
| All | No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.25(0.19–0.31) | 0.00 | 0.25(0.19–0.31) | 0.00 | 0.29(0.22–0.37) | 0.00 | 0.29(0.23–0.37) | 0.00 | |
|
| |||||||||
| Male | No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.23(0.16–0.32) | 0.00 | 0.23(0.16–0.33) | 0.00 | 0.27(0.19–0.38) | 0.00 | 0.27(0.19–0.39) | 0.00 | |
|
| |||||||||
| Female | No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.26(0.19–0.36) | 0.00 | 0.26(0.19–0.35) | 0.00 | 0.30(0.22–0.42) | 0.00 | 0.31(0.22–0.43) | 0.00 | |
aAdjusted for gender, age (continuous variable), education, and profession.bAdditionally adjusted for hypertension.cAdditionally adjusted for BMI, waist circumference, FBG, OTGG-2h, HbA1c, TC, LDL-C, and UA.dAdditionally adjusted for TSH and TGAb.